BDX vs SOLV
Becton Dickinson and Solventum, both Healthcare
Becton Dickinson is the larger company at $40B against $13B. On trailing earnings SOLV is the cheaper of the two at a P/E of 10.7 against 55.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year BDX returned +26% against +17% for SOLV. The RyuScore puts SOLV ahead, 69 against 62 out of 100.
| Figure | BDX | SOLV |
|---|---|---|
| Last close | $184 | $87.38 |
| Market cap | $40B | $13B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 55.3 | 10.7 |
| Dividend yield | 2.3% | n/a |
| 1-year return | +26% | +17% |
| 5-year return | +0.7% | n/a |
| RyuScoresector-relative, 1–10 | 62/100 | 69/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Becton Dickinson
Revenue of $5.0B in Q3 2026, net income $377M. Its largest reported line is Connected Care, 38% of the disclosed total.
Solventum
Revenue of $2.2B in Q2 2026, net income $92M. Its largest reported line is Med Surg, 42% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.